| Pharmaceutical Information |
| Drug Name |
Lodoxamide |
| Drug ID |
BADD_D01307 |
| Description |
Lodoxamide is a mast-cell stabilizer for topical administration into the eye. Mast-cell stabilizers, first one approved being cromolyn sodium, are used in treatment of ocular hypersensitivity reactions such as vernal conjunctivitis. These conditions often require treatment with anti-inflammatory medications such as ophthalmic NSAIDs or topical steroids which may cause systemic or toxic effects long-term. Although less effective than topical steroids at decreasing inflammation, mast-cell stabilizers offer another treatment option and exhibit minimal adverse effects. Lodoxamide is marketed under the brand name Alomide by Alcon. |
| Indications and Usage |
Indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |
| Marketing Status |
approved |
| ATC Code |
S01GX05 |
| DrugBank ID |
DB06794
|
| KEGG ID |
D08139
|
| MeSH ID |
C021702
|
| PubChem ID |
44564
|
| TTD Drug ID |
D0OG3K
|
| NDC Product Code |
58567-102 |
| UNII |
SPU695OD73
|
| Synonyms |
lodoxamide ethyl | diethyl N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate | U-42,718 | lodoxamide |
|
| Chemical Information |
| Molecular Formula |
C11H6ClN3O6 |
| CAS Registry Number |
53882-12-5 |
| SMILES |
C1=C(C=C(C(=C1NC(=O)C(=O)O)Cl)NC(=O)C(=O)O)C#N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Sensation of foreign body | 08.01.09.002 | - | - | Not Available |
|
|
|
